Recently, DelSiTech Ltd. ("DelSiTech"), a Finland
based drug delivery company entered into a patent licensing
agreement over DelSiTech's patents with Visus Therapeutics
("Visius"), a US based company. This is a worldwide
exclusive licensing agreement. Both companies are working on six
development programmes for eye care solutions targeting the
management of ocular diseases of the back and front of the eye.
DelSiTech Ltd, a leader in advanced, biodegradable,
silica-based, controlled-release materials, to develop novel drug
delivery technology that can help optimize the clinical benefit of
therapies. DelSiTech has developed this patented drug delivery
technology platform (Silica Matrix) that enables the extended
release of drugs in a wide range of tissues, including the
intravitreal space inside the eye. Furthermore, the matrix
dissolves as the drug is released without leaving any residue in
the eye. This technology therefore provides a distinct advantages
over
